Stereotaxis establishes first robotic heart procedure program in Italy
Stereotaxis (NYSE:STXS) announced today that a hospital in Italy established the first robotic cardiac heart program in the region.
Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, established the program. Now, doctors there can treat patients with heart rhythm disorders using robotic ablation procedures. The hospital becomes the first in Italy to adopt the Stereotaxis Genesis robotic magnetic navigation (RMN) system.
Stereotaxis RNM utilizes robotic precision and safety for cardiac ablation. Genesis utilizes smaller magnets that rotate along their center of mass, allowing for responsiveness to physician control. The smaller system can improve the patient experience, provide greater patient access and increase lab space. Flexible, rugged robotic arms hold the agents to increase the potential range of motion and allow for wider X-ray angulation.
Dr. Mario Volpicelli, head of the hospital’s electrophysiology unit, said Genesis provides “an unprecedented level of precision and control” in cardiac ablation. Volpicelli added that it helps to target arrhythmias accurately while minimizing the risk to patients.
“We are honored to partner with Hospital Santa Maria della Pietà in bringing the benefits of robotics to patients in Italy,” said David Fischel, Stereotaxis chair and CEO. “The adoption of the Genesis system reflects our shared commitment to advancing standard of care, innovation, and patient-focused solutions in electrophysiology.”
A hospital in Kentucky performed the first procedures with the Genesis surgical robotic system late last year. Stereotaxis also has an ongoing surgical robotics collaboration with Abbott, which had milestone developments last fall. The company features on MassDevice’s 2024 list of 10 surgical robotics companies you need to know.
